Julie Steenhuysen
Julie Steenhuysen
CRITIC
img-contested
N/A
0 reviews
PUBLIC
img-contested
N/A
0 reviews

RECENT ARTICLES

Sort by:
No Rating
Fauci says he believes J&J vaccine will ‘get back on track soon’

Fauci says he believes J&J vaccine will ‘get back on track soon’

Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/IllustrationAnthony Fauci, the top U.S. infectious disease doctor, hopes U.S. regulators will make a quick decision to lift a pause on the Johnson & Johnson vaccine and get that vaccine “back on track,” he said in an interview with Reuters on Thursday.His...

Apr 15
Share
Save
Review
No Rating
Exclusive: Fauci says U.S. may not need AstraZeneca COVID-19 vaccine

Exclusive: Fauci says U.S. may not need AstraZeneca COVID-19 vaccine

By CHICAGO (Reuters) - The United States may not need AstraZeneca’s COVID-19 vaccine, even if it wins U.S. regulatory approval, Anthony Fauci, the nation’s top infectious disease doctor told Reuters on Thursday.The vaccine, once hailed as another milestone in the fight against the COVID-19 pandemic, has been dogged by questions since late last year, even as it has been authorized for use by dozens of countries, not including United States.Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to the White House, said the United States has...

Apr 1
Share
Save
Review
No Rating
T cells induced by COVID-19 infection respond to new virus variants: U.S. study

T cells induced by COVID-19 infection respond to new virus variants: U.S. study

By CHICAGO (Reuters) - A critical component of the immune system known as T cells that respond to fight infection from the original version of the novel coronavirus appear to also protect against three of the most concerning new virus variants, according to a U.S. laboratory study released on Tuesday.Several recent studies have shown that certain variants of the novel coronavirus can undermine immune protection from antibodies and vaccines.But antibodies - which block the coronavirus from attaching to human cells - may not tell the whole story, according to the study by researchers at the...

Mar 30
Share
Save
Review
No Rating
U.S. authorizes Johnson & Johnson's COVID-19 vaccine

U.S. authorizes Johnson & Johnson's COVID-19 vaccine

By (Reuters) - The U.S. government on Saturday authorized Johnson & Johnson’s single-dose COVID-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting it up for additional approvals around the world.The U.S. Food and Drug Administration announced the emergency use authorization for adults aged 18 and older following Friday’s unanimous endorsement by the agency’s panel of outside experts.“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic,...

Feb 27
Share
Save
Review
No Rating
Fresh data show toll South African virus variant takes on vaccine efficacy

Fresh data show toll South African virus variant takes on vaccine efficacy

By CHICAGO (Reuters) - Clinical trial data on two COVID-19 vaccines show that a coronavirus variant first identified in South Africa is lessening their ability to protect against the illness, underscoring the need to vaccinate vast numbers of people as quickly as possible, scientists said.The vaccines from Novavax Inc and Johnson & Johnson were welcomed as important future weapons in curbing deaths and hospitalizations in a pandemic that has infected more than 101 million people and claimed over 2 million lives worldwide.But they were significantly less effective at preventing COVID-19 in...

Jan 30
Share
Save
Review
No Rating
Exclusive: FDA chief had 'robust discussion' with White House about vaccine timelines

Exclusive: FDA chief had 'robust discussion' with White House about vaccine timelines

By , WASHINGTON (Reuters) - The U.S. Food and Drug Administration’s chief had a “robust discussion” with the White House this week about the timeline for coronavirus vaccine approvals and believes vaccinating 20 million Americans this year is realistic, he said on Friday.FDA Commissioner Stephen Hahn declined to lay out a specific timetable for approval of the vaccine developed by Pfizer and BioNTech but said he hoped the regulator would make a decision this month.Many federal officials are expecting a vaccine approval within days of a Dec. 10 meeting of experts, though one FDA official...

+1
December 4, 2020
Share
Save
Review
No Rating
We can stop COVID-19: Moderna vaccine success gives world more hope

We can stop COVID-19: Moderna vaccine success gives world more hope

By , The vaccines, both developed with new technology known as messenger RNA (mRNA), represent powerful tools to fight a pandemic that has infected 54 million people worldwide and killed 1.3 million.Unlike Pfizer’s vaccine, Moderna’s shot can be stored at normal fridge temperatures, which should make it easier to distribute, a critical factor as COVID-19 cases are soaring, hitting new records in the United States and pushing some European countries back into lockdowns.“We are going to have a vaccine that can stop COVID-19,” Moderna President Stephen Hoge said in a telephone...

+1
November 16, 2020
Share
Save
Review
No Rating
Fauci not advising Biden, sees no reason to quit Trump now - Reuters interview

Fauci not advising Biden, sees no reason to quit Trump now - Reuters interview

By CHICAGO (Reuters) - Dr. Anthony Fauci, the top U.S. infectious disease expert, said he has had no contact with President-elect Joe Biden’s coronavirus transition team and sees no reason to quit to join that effort when there is so much to do now to fight the surging pandemic.“I stay in my lane. I’m not a politician. I do public health things,” he said in an interview on Thursday ahead of next week’s Reuters Total Health conference.Since January, Fauci has served on President Donald Trump’s White House Coronavirus Task Force, a position that has frequently put him at odds with the...

November 13, 2020
Share
Save
Review
No Rating
'Great day for humanity': Pfizer says COVID-19 vaccine over 90% effective

'Great day for humanity': Pfizer says COVID-19 vaccine over 90% effective

By , Health experts said Pfizer’s results were positive for all COVID-19 vaccines currently in development since they show the shots are going after the right target and are a proof of concept that the disease can be halted with vaccination.“Today is a great day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive, said.“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”If Pfizer’s vaccine is...

+1
November 9, 2020
Share
Save
Review
No Rating
Fauci says first U.S. COVID-19 vaccines could ship late December or early January

Fauci says first U.S. COVID-19 vaccines could ship late December or early January

By CHICAGO (Reuters) - If all goes well, the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January, Dr. Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday.Slideshow Based on current projections from vaccine front-runners Moderna Inc and Pfizer Inc, Americans will likely know “sometime in December whether or not we have a safe and effective vaccine,” Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a live chat on Twitter and Facebook.“The...

October 29, 2020
Share
Save
Review
  • Total 15 items
  • 1
  • 2
OUTLETS
reuters.com

reuters.com

CRITIC
img-trusted
100%
PUBLIC
img-trusted
75%